BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Circassia Limited's Cat Allergy Treatment Shows Sustained Symptom Improvement


2/25/2013 10:53:48 AM

25 February 2013 -- Imperial Innovations Group plc (AIM: IVO, ‘Innovations’ or ‘the Group’), a leading technology commercialisation and investment group, announces that portfolio company Circassia, the speciality biopharmaceutical company focused on allergy, has seen strong results from its follow up phase II clinical trial.

Patients saw a sustained improvement of their cat allergy symptoms two years after they started a four-dose, 12 week course of Circassia’s ToleroMune® cat allergy treatment.

The phase II study originally measured the level of patients’ symptoms following Toleromune® treatment, compared with placebo. Two years later, and having received no further ToleroMune® treatment, 50 of the original 202 patients were reassessed. The study showed that these patients maintained consistent symptom improvements both 12 and 24 months after the start of the treatment and found that the treatment reduced symptoms by two and a half to three times the level achieved by other allergy therapies in similar studies.

Circassia is currently conducting a phase III multinational study to test the safety and efficacy of the ToleroMune® treatment in approximately 1,200 subjects from the United States, Canada and Europe and results are expected in 2014.

The ToleroMune® allergy treatment is based on an approach of using synthetic peptides identified from allergens to induce immune tolerance in the body by generating regulatory T-cells which suppress allergic responses.

Allergies are a significant global health issue. Tens of millions of people are allergic to cats in the United States and Europe, and the disease can have a major effect on patients’ quality of life. Currently no short, simple treatment with a long-lasting impact on the disease is available.

Allergic rhinoconjunctivitis (ARC) affects 30% of adults and 40% of children in developed countries, and the prevalence is rising. In Continental Europe and the US, cat-allergen induced ARC, for which the ToleroMune® cat allergy treatment is designed, is one of the commonest forms and affects 10-15% of those with ARC or asthma.

These long term results of Circassia’s phase II trial were presented at the 2013 Annual Meeting of the American Academy of Allergy, Asthma and Immunology (AAAAI) in San Antonio, USA on Sunday 24 February.

Circassia has also completed successful phase II studies for its treatments for grass, house dust mite and ragweed allergies.

Susan Searle, Chief Executive Officer, Imperial Innovations, said:

“These strong long-term results for Circassia’s cat allergy treatment are very exciting and reinforce the great potential of the business and its ToleroMune® platform. Circassia is one of our largest assets and this success endorses our approach to building larger companies for longer.”

Steve Harris, Chief Executive Officer of Circassia, said:

“We are extremely encouraged by these excellent clinical results which strongly support our decision to progress our cat allergy treatment trials to phase III. Offering patients sustained symptom control without the need for ongoing treatment is an important objective for allergy therapy. Our ToleroMune® treatment reduced symptoms by two and a half to three times the level achieved by several other allergy therapies in similar studies, and has now been shown to maintain that improvement for the long-term, demonstrating its potential to greatly improve the lives of patients around the world.”

Enquiries:

Imperial Innovations +44 (0)20 7594 6589

Susan Searle, Chief Executive Officer

Terry Nicklin, Director of Communications

Gavin Reed, Marketing Assistant

Circassia +44 (0)1865 784574

Steve Harris, Chief Executive Officer

College Hill +44 (0)20 7457 2020

Adrian Duffield/Rozi Morris/Melanie Toyne Sewell/Tim Watson

J.P. Morgan Cazenove +44 (0)20 7742 4000

Michael Wentworth-Stanley/Paul Park

Imperial Innovations - www.imperialinnovations.co.uk

Innovations creates, builds and invests in pioneering university technologies addressing global problems in healthcare, energy, engineering and the environment. It combines deep understanding of science and technology with commercial acumen and strong investment expertise.

Innovations supports scientist-entrepreneurs in the commercialisation of their ideas by:

• leading the formation of new companies and providing facilities in the early stages

• providing significant investment and encouraging co-investment to accelerate the transition from R&D to products

• providing operational expertise

• helping to recruit high-calibre industry figures and experienced entrepreneurs as executive management and Board members

Innovations invests in companies based on technologies from or associated with four universities: Imperial College London; and Cambridge University, Oxford University, and UCL supported by its collaborations with Cambridge Enterprise, OSEM and UCL Business. These are the UK’s leading research intensive universities, measured by research income.

By raising £140 million in January 2011, Innovations has been able to accelerate the making of, and increase the size of its investments. In the year to 31 July 2012, Innovations invested £37.9 million (2011: £35.1 million) in 29 ventures, and made 11 investments in new companies.

In its current portfolio of 78 companies, Innovations’ most advanced assets include Circassia, which develops innovative treatments for a wide range of allergies; and Nexeon, a battery materials and licensing company which develops silicon anodes which extend the life and increase the capacity of lithium-ion batteries.

Circassia – www.circassia.co.uk

Circassia was founded by a team of highly experienced biotechnology scientists and entrepreneurs. The company is based in the UK on the Oxford Science Park, and its joint venture with McMaster University (Adiga Life Sciences Inc) is located in Hamilton, Canada. Circassia’s ToleroMune® technology was developed originally by scientists at Imperial College, London. Having successfully completed five fundraising rounds, Circassia has raised approximately £105 million ($178 million) and is backed by a syndicate of world-class institutional investors, including Imperial Innovations and Invesco Perpetual.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES